Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications (Wiley Series in Drug Discovery and Development)

0.0

Brings together functional and structural informationrelevant to the design of drugs targeting zinc enzymesThe second most abundant transition element in living organisms, zinc spans all areas of metabolism, with zinc-containing proteins offering both established and potential drug targets. Drug Design of Zinc-Enzyme Inhibitors brings together functional and structural information relevant to these zinc-containing targets. With up-to-date overviews of the latest developments field, this unique and comprehensive text enables readers to understand zinc enzymes and evaluate them in a drug design context.With contributions from the leaders of today's research, Drug Design of Zinc-Enzyme Inhibitors covers such key topics as:Major drug targets like carbonic anhydrases, matrix metalloproteinases, bacterial proteases, angiotensin-converting enzyme, histone deacetylase, and APOBEC3GRoles of recently discovered zinc-containing isozymes in cancer, obesity, epilepsy, pain management, malaria, and other conditionsCross reactivity of zinc-enzyme inhibitors and activatorsThe extensive use of X-ray crystallography and QSAR studies for understanding zinc-containing proteinsClinical applicationsAn essential resource for the discovery and development of new drug molecules, Drug Design of Zinc-Enzyme Inhibitors gives researchers, professionals, students, and academics the foundation to understand and work with zinc enzyme inhibitors and activators.

0.0

Claudiu T. Supuran is a professor in the Department of Chemistry at the University of Florence, Italy. His main research interests include medicinal chemistry, design of enzyme inhibitors and activators, X-ray crystallography of metallo-enzymes, and metal complexes with biologically active ligands (metal-based drugs). He has published more than 400 original research papers in these fields.Jean-Yves Winum is an assistant professor in the Department of Chemistry at the University of Montpellier 2 (Institut des Biomolécules Max Mousseron UMR CNRS 5247), France. His research interests are focused on organic/medicinal chemistry of metallo-enzyme inhibitors and activators.